Amyris expands precision fermentation line in Brazil

Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M

Ichnos Glenmark Innovation’s full dose-escalation data show high response rates of ISB 2001

Sigachi Industries FY25 revenue surges 25%, EBITDA 46%

Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients

SeQuent–Viyash merger receives stock exchange approvals; NCLT filing underway

Revvity introduces new IVD reference standards for monitoring oncology diagnostic testing workflows

Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows

Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio

ICN to organize virtual discussion on "Digital Transformation: The Catalyst for Agile and Smarter Process" on June 4

Speakers for the session are: Dr. Richard Lobo, Global Head Business Excellence, Innovation, R&D and Chief Ethics Counsellor, Tata Chemicals; Dr. Debabrata Rautaray, Vice President and Chief Product Development & Innovation Officer, DCM Shriram Chemicals Innovation Centre; Dr. Prashant Puri, Head - R&D, Deepak Fertilizers and Petrochemicals Corporation (DFPCL); Dr. Deepak S Panmand, General Manager (R&D), Dhanuka Agritech; Dr. Mudassir. K. Munshi, Team Leader, Deepak Nitrite; and Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals

Sudeep Pharma acquires Nutrition Supplies Services

This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio

Alkem reports 7.1% YoY revenue growth in Q4 FY25

Annual EBITDA margin expands by 170 basis points

Pimicotinib demonstrates best-in-class potential with significant efficacy and clinically meaningful improvements in patients with tenosynovial giant cell tumor

MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume